These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29718453)

  • 1. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.
    Loree JM; Bailey AM; Johnson AM; Yu Y; Wu W; Bristow CA; Davis JS; Shaw KR; Broaddus R; Banks KC; Lanman RB; Meric-Bernstam F; Overman MJ; Kopetz S; Raghav K
    J Natl Cancer Inst; 2018 Dec; 110(12):1409-1417. PubMed ID: 29718453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.
    Kang M; Shen XJ; Kim S; Araujo-Perez F; Galanko JA; Martin CF; Sandler RS; Keku TO
    Cancer Biomark; 2013; 13(5):359-66. PubMed ID: 24440976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
    Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S
    Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.
    Liu Y; Bischof E; Chen Z; Zhou J; Zhang B; Zhang D; Gao Y; Quan M
    Oncol Res; 2024; 32(9):1429-1438. PubMed ID: 39220126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.
    Laforest A; Aparicio T; Zaanan A; Silva FP; Didelot A; Desbeaux A; Le Corre D; Benhaim L; Pallier K; Aust D; Pistorius S; Blons H; Svrcek M; Laurent-Puig P
    Eur J Cancer; 2014 Jul; 50(10):1740-1746. PubMed ID: 24797764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
    Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
    Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
    Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
    Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
    World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
    Domingo E; Camps C; Kaisaki PJ; Parsons MJ; Mouradov D; Pentony MM; Makino S; Palmieri M; Ward RL; Hawkins NJ; Gibbs P; Askautrud H; Oukrif D; Wang H; Wood J; Tomlinson E; Bark Y; Kaur K; Johnstone EC; Palles C; Church DN; Novelli M; Danielsen HE; Sherlock J; Kerr D; Kerr R; Sieber O; Taylor JC; Tomlinson I
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):635-643. PubMed ID: 30042065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
    Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
    Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
    Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
    PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.
    Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M
    Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
    Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
    J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
    Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
    BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.